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Abstract
Background: The cellular response of malignant tumors to hypoxia is diverse. Several important endogenous
metabolic markers are upregulated under hypoxic conditions. We examined the staining patterns and co-
expression of HIF-1a, CAIX, LDH-5, GLUT-1, MCT1 and MCT4 with the exogenous hypoxic cell marker pimonidazole
and the association of marker expression with clinicopathological characteristics.
Methods: 20 biopsies of advanced head and neck carcinomas were immunohistochemically stained and analyzed.
All patients were given the hypoxia marker pimonidazole intravenously 2 h prior to biopsy taking. The tumor area
positive for each marker, the colocalization of the different markers and the distribution of the markers in relation
to the blood vessels were assessed by semiautomatic quantitative analysis.
Results: MCT1 staining was present in hypoxic (pimonidazole stained) as well as non-hypoxic areas in almost equal
amounts. MCT1 expression showed a significant overall correlation (r = 0.75, p < 0.001) and strong spatial
relationship with CAIX. LDH-5 showed the strongest correlation with pimonidazole (r = 0.66, p = 0.002). MCT4 and
GLUT-1 demonstrated a typical diffusion-limited hypoxic pattern and showed a high degree of colocalization. Both
MCT4 and CAIX showed a higher expression in the primary tumor in node positive patients (p = 0.09 both).
Conclusions: Colocalization and staining patterns of metabolic and hypoxia-related proteins provides valuable
additional information over single protein analyses and can improve the understanding of their functions and
environmental influences.
Background
Malignant tumors often exhibit an altered metabolism
compared to normal tissues. This phenomenon can be
explained by several underlying mechanisms. First of all,
the genetic changes related to a high proliferation rate,
as observed in many tumors, lead to an increased meta-
bolism[1]. Another important reason for a changed
metabolism is the adaptation of tumor cells to the
microenvironment. Due to rapid tumor growth, hypoxic
areas are frequently encountered. Under circumstances
of severe hypoxia, cells are forced to use anaerobic gly-
colysis as their primary energy source, the Pasteur effect
[2]. Normal cells convert to oxidative phosphorylation
when oxygen levels are restored. In contrast, tumor cells
can use aerobic glycolysis even in the presence of suffi-
cient amounts of oxygen. This is called the Warburg
effect, a manifestation of a modification of the tumor
cell metabolism[3]. Due to a high level of aerobic glyco-
lysis, in many tumor cells, glucose consumption is sub-
stantially higher than in normal cells [4,5].
The consequence of the high rate of glycolysis in malig-
nant cells is the production of large amounts of lactic
acid. An interesting observation made by Sonveaux et al.
is the preference of tumor cells for lactic acid over glu-
cose as the primary energy source [6]. This creates the
perfect conditions for a symbiosis between anaerobic gly-
colytic cells and aerobic tumor cells [6] or aerobic stro-
mal cells, as described in colorectal carcinomas [7].
Recently, monocarboxylate transporters (MCT’s) have
been discovered to play an important role in this symbio-
sis. These transporters facilitate the uptake and excretion
of monocarboxylates, like lactate and pyruvate, and act as
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affinity/high capacity lactate transporter, which is abun-
dantly present in highly glycolytic muscle cells. It is one of
the many target genes of hypoxia-inducible factor 1 (HIF-
1)[9]. MCT1 is a high-affinity, low capacity monocarboxy-
late transporter, found in normal tissues like the intestinal
epithelium (executing an important role in organic acid
absorption), the blood brain barrier, red blood cells and
skeletal muscle cells. Its expression seems to be regulated
by multiple signaling pathways, microenvironmental para-
meters, changes in substrate concentration and pH[8].
Other important proteins related to the metabolism of
tumor cells are glucose transporter-1 (GLUT-1), the main
transporter involved in glucose influx, and lactate dehy-
drogenase-5 (LDH-5), responsible for the conversion of
pyruvate into lactate. Like MCT4, these proteins are upre-
gulated under hypoxic conditions by HIF-1[10]. Another
main target for HIF-1 is carbonic anhydrase IX (CAIX), a
hypoxia-related protein involved in pH regulation[11], that
shows weak correlations with the exogenous hypoxia mar-
ker pimonidazole[12,13]. The advantage of the use of
these proteins as endogenous immunohistochemical mar-
kers is that no prior infusion of markers is necessary and
therefore archived material can be used to assess the meta-
bolic and, possibly, the hypoxic status of the tumor. How-
ever, up until now no endogenous marker has been
identified that correlates strongly with pimonidazole[14].
In this study, we describe and quantify the expression pat-
terns and colocalization of several important hypoxia-
related and metabolic marke r si nb i o p s i e so fh e a da n d
neck tumors and in particular the association with pimoni-
dazole as the reference exogenous hypoxic marker[15].
Methods
Samples
The study was approved by the local ethics committee. 20
biopsies from 18 head and neck tumors were included in
the analysis; from two tumors two biopsies were available.
All patients received pimonidazole (1-((2-hydroxy-3-piperi-
dinyl)propyl)-2-nitroimidazole hydrochloride, Hypoxyp-
robe-1; Natural Pharmacia International, Belmont, MA)
intravenously (500 mg/m
2 ) two hours before biopsy tak-
ing. Pimonidazole is a bioreductive chemical probe that
forms protein adducts in viable hypoxic cells. Biopsies were
snap frozen in liquid nitrogen and stored until further pro-
cessing. The samples were cut in sections of 5 μma n d
stained by immunofluorescence for pimonidazole, HIF-1a,
CAIX, GLUT-1, LDH-5, MCT1, MCT4 and vessels in dif-
ferent combinations of 3 markers per tissue section.
Immunohistochemistry
For immunohistochemical processing, the sections were
fixed for 10 minutes in acetone and rehydrated in PBS
0.1 mol/L (pH 7.4) (Klinipath, Duiven, The
Netherlands). Between all consecutive steps of the stain-
ing procedure the sections were rinsed thrice for 5 min-
utes in PBS.
For detection of pimonidazole, sections were incu-
bated with rabbit-anti-pimo antibody (J.A. Raleigh,
Department of Radiation Oncology and Toxicology,
University of North Carolina, Chapel Hill, North Caro-
lina, USA) diluted 1:1000 in primary antibody diluent
(PAD, Abcam, Cambridge, UK) for 30 minutes at 37°C.
The second incubation step was with donkey-anti-rabbit
Alexa488 (Molecular Probes, Leiden, The Netherlands)
diluted 1:600 in PBS. Staining for vessels was done by
incubation with the mouse antibody PAL-E (Euro Diag-
nostica, Arnhem, The Netherlands) diluted 1:10 in PAD,
followed by incubation with chicken-anti-mouse
Alexa647 (Molecular Probes) for 60 min at 37°C diluted
1:100 in PBS.
T h es a m es e c o n d a r ya n t i b o d y( i nad i f f e r e n tt i s s u e
section) was used to detect CAIX, after incubation with
mouse-anti-CAIX antibody (E. Oosterwijk, Department
of Urology, University Medical Center, Nijmegen),
diluted 1:25 in PAD for 30 min at 37°C.
For detection of MCT1, sections were incubated with
goat-anti-MCT1 (Santa Cruz)[7], 1:100 in PAD, over-
night at 4°C. The next day the secondary antibody was
added: donkey-anti-goatCy3 (Jackson Immuno Research
Laboratories Inc., West Grove, PA, USA) 1:600 in PBS,
30 min at 37°C.
Staining for MCT4 was done by incubation with rabbit-
anti-MCT4 (Santa Cruz)[16], 1:100 in PAD, overnight at
4°C. The secondary antibody was either goat-anti-rabbit-
FabCy3 (1:600 in PBS) or donkey-anti-rabbitAlexa488
(1:600 in PBS) depending on the combination of markers
stained in that tissue section.
Sections were incubated with rabbit-anti-GLUT-1
(Neomarkers, Fremont, CA, USA.), diluted 1:100 in
PAD for 30 min at 37°C, followed by donkey-anti-rabbi-
tAlexa488, 1:600 in PBS for 30 min at 37°C for detection
of GLUT-1.
Staining for HIF-1a was done by incubation with rab-
bit-anti-HIF-1a (Santa Cruz), diluted 1:50 in PAD over-
night at 4°C, followed by goat-anti-rabbitCy3 (Jackson
Immuno Research Laboratories Inc.), 1:600 in PBS for
30 min at 37°C. In the same section, all nuclei were
stained with Hoechst (Sigma, Zwijndrecht), 0.33 μg/ml,
in PBS for 5 min at room temperature.
Finally, for detection of LDH-5 sections were incu-
bated with sheep-anti-LDH-5 (Abcam), diluted 1:100 in
PAD overnight at 4°C. The next day, incubation with
donkey-anti-sheepCy3 (Jackson Immuno Research
Laboratories Inc.), 1:600 in PBS for 30 min at 37°C,
completed the staining.
All sections were mounted in fluorostab (ProGen Bio-
technik GmbH, Heidelberg, Germany).
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Page 2 of 10Image acquisition and analysis
T h et i s s u es e c t i o n sw e r es c a n n e du s i n gad i g i t a li m a g e
processing system consisting of a high-resolution 12-bit
CCD camera (Micromax, Roper Scientific Inc., Trenton,
NJ, USA) on a fluorescence microscope (Axioskop,
Zeiss, Göttingen, Germany) and a computer-controlled
motorised stepping stage. Image processing was done
using IPLab software (Scanalytics Inc., Fairfax, VA,
USA) on a Macintosh computer[17]. Each tissue section
was sequentially scanned for the three signals at 100×
magnification with a resolution of 2.6 μm/pixel. The
resulting composite grey scale images were converted to
binary images for further analysis. Thresholds for the
fluorescent signals were interactively set above the back-
ground for each individual marker. The composite grey
scale images were superimposed into one pseudocolored
image for visual evaluation.
Guided by an H&E stained consecutive section, the
tumor area of each section was delineated. This area was
subsequently used as a mask in further analysis from
which non-tumor tissue, large necrotic areas and artefacts
were excluded. The marker fractions were defined as the
tumor area positive for the marker, divided by the total
tumor area. With this method, an automated quantitative
analysis of the percentage of positively stained tumor tis-
sue can be obtained. To determine the colocalization of
the various markers with pimonidazole, the relative area
positive within and outside the pimonidazole stained area
was calculated. Similar analyses were done to assess the
colocalization between MCT1, MCT4, GLUT-1 and
CAIX.
The spatial distribution of the markers in relation to the
blood vessels was measured by calculating the relative area
positive in six zones around the closest vessels with a
width of 50 μm each (0-50 μm, 50-100 μm, 100-150 μm,
150-200 μm, 200-250 μm and >250 μm)[17]. As the abso-
lute fractions differ greatly, normalisation of fractions was
performed for clear comparison of distributions. Quantita-
tive analysis of the HIF-1a staining was not possible
because of the low signal-to-background ratio in many
HIF-1a-positive areas. All sections were visually scored by
two observers and divided in two groups; high and low
HIF-1a expression based on the intensity and the esti-
mated fraction of HIF-1a positive cells. Differences
between the observers were resolved at the microscope.
Statistics
Statistical analyses were done with Prism software pack-
age for Macintosh. The relationships between metabolic
parameters (as continuous variables) were tested using
the Spearman rank correlation coefficient or the Pearson
correlation coefficient as appropriate. Differences in
colocalization were analyzed with a Mann-Whitney test.
To test the association of the markers with categorical
tumor characteristics (T-stage, N-stage and histopatho-
logical grade) either the Mann-Whitney test or Fisher’s
exact test (after dichotomization of the variables) was
used.
Results
20 biopsies of 18 patients with histologically confirmed
advanced stage squamous cell carcinoma of the head
and neck were included in this study. Tumor character-
istics are shown in Table 1.
Correlation between metabolic markers and tumor
characteristics
A trend to a higher expression of both MCT4 and CAIX
in node positive patients was observed (p = 0.09 both)
(Figure 1). After dichotomization of the variables MCT4
expression was significantly higher in node positive
patients (p = 0.01). HIF-1a only showed a trend towards
higher expression in node positive patients (p = 0.06),
although HIF-1a expression was only found in one
node negative tumor. In this biopsy the HIF-1a expres-
sion as well as the pimonidazole staining was found in
well-differentiated areas around keratinization. T4
tumors showed a significantly lower pimonidazole stain-
ing (p = 0.02) and CAIX expression (p = 0.03) than T2
or T3 tumors. This inverse trend was found for MCT1
and MCT4 as well (p = 0.09 and p = 0.08 respectively).
No correlations were found between any of the markers
and differentiation grade.
Staining patterns
Examples of staining of all markers are shown in Figure 2.
Pimonidazole fraction ranged from 0 - 34% (median 7%)
and different hypoxic patterns were observed. Some
tumors showed a typical ribbon-like pattern, others a
Table 1 Tumour site, stage and grade
Characteristics Number
Tumour site
Larynx 7
Hypopharynx 4
Oropharynx 5
Oral cavity 2
T stage
T2 3
T3 6
T4 9
N stage
N0 6
N+ 12
Histopathological grade
Moderately differentiated 14
Poorly differentiated 4
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Page 3 of 10more patchy pattern[18]. (Figure 2a/b) Extensive cytoplas-
mic LDH-5 expression was seen in most of the tumors
(fraction range 17 - 91%, median 37%, figure 2c), with
more intense staining in hypoxic areas.
Membranous CAIX expression closely followed the
hypoxic pattern in some tumors, in others CAIX stain-
ing showed less spatial correlation with pimonidazole.
The fraction ranged from 0 - 43% (median 4.7%)
(Figure 2a, b, d).
MCT 1 showed a clear membranous staining pattern
with substantial variation in intensity and extent; in
some sections large MCT1 positive areas were seen, in
other sections almost no MCT1 was present (fraction
range 0.1 - 64%, median 14%). MCT1 staining was not
only observed adjacent to hypoxic areas, but also within
hypoxic areas (Figure 2e).
MCT 4 showed a more diffuse staining pattern, with
fractions varying from 0.6 - 49% (median 14%) and with
more staining at increasing distance from the vessels.
GLUT-1 had a comparable staining pattern to MCT4
(fraction range 3 - 43%, median 18%): diffuse staining
throughout the tissue section, with more staining at
increasing distance from the vessels. (Figure 2f/g)
Apparent localised nuclear HIF-1a staining was pre-
sent in 15 out of 20 biopsies, mostly in and around
hypoxic areas (Figure 2h) with large variation in inten-
sity. In some tissue sections membranous or cytoplas-
matic staining was present as well, but only nuclear
staining was taken into account.
Correlations between markers
To get a global impression of the associations between
the six markers overall correlations were calculated, irre-
spective of the geographical distribution. (Figure 3) The
strongest correlation with pimonidazole was observed for
LDH-5 fraction (r = 0.66, p = 0.002). CAIX showed sig-
nificant correlations with MCT1, MCT4 and GLUT-1.
The expression of the endogenous markers was com-
pared between biopsies with a high and low HIF-1a expres-
sion. (Figure 3) Overall, biopsies with a high HIF-1a
expression demonstrated a significantly higher CAIX frac-
tion. Remarkably, two biopsies clearly showed HIF-1a
expression, but very low fractions of CAIX, GLUT-1 and
MCT4. In one of the biopsies pimonidazole staining was
associated with well-differentiated keratinizing areas as
described by Janssen et al. [19], the other biopsy showed no
pimonidazole staining at all. Overall, mean pimonidazole
staining was equal in biopsies with high and low HIF-1a
expression. A schematic representation of the associations
b e t w e e nt h em a r k e r si ss h o w ni nF i g u r e3 .
Colocalization of metabolic and hypoxic markers
The results of the quantitative analysis of the colocaliza-
tion of the various markers are shown in Figure 4.
MCT4 expression was significantly higher in hypoxic
areas than in non-hypoxic areas (p = 0.001) and also
clearly correlated to CAIX expression. GLUT-1 expres-
sion and MCT4 expression showed an even stronger
amount of colocalization with approximately six times
higher GLUT-1 expression in MCT4 positive areas.
MCT1 was present in well-oxygenated areas, but
unexpectedly showed considerable expression in hypoxic
areas as well (no significant difference, p = 0.11). Addi-
tionally, MCT1 expression was significantly correlated
with CAIX expression (p < 0.001). Pimonidazole stained
areas exhibited, beside MCT4, a significantly higher
expression of CAIX and LDH-5 compared to pimonida-
zole negative areas.
Although colocalization with HIF-1a expression could
not be analyzed in the same manner as the other mar-
kers, it was observed that pimonidazole-related CAIX
areas showed more intense HIF-1a expression than
Figure 1 MCT4 and CAIX expression according to nodal stage.
A significantly higher expression of MCT4 (p = 0.04, a) and CAIX (p
= 0.05, b) was found in node-positive tumours. One tumor without
nodal metastasis had a high CAIX expression of 17%. Interestingly,
no HIF-1a expression was found in this tumor.
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Page 4 of 10Figure 2 Immunofluorescent staining pattern of metabolic and hypoxic markers. (a and b) Fluorescent microscopic images of two head
and neck carcinomas with different pimonidazole (green) and CAIX (blue) staining patterns. (c - h) Examples of staining of the various markers.
(c) LDH-5 (red), pimonidazole (green) and vessels (white). (d) Perinecrotic pimonidazole (green) and CAIX (red) staining, N = Necrosis. (e) MCT1
(red), pimonidazole (green) and vessels (white), note the co-staining of MCT1 with pimonidazole. (f and g) Membranous GLUT-1 (f) and MCT4 (g)
(both red) staining in relation to the vessels (white). (h) Nuclear HIF-1a (red) expression in relation to pimoniazole (green) staining. (i and j)
Fluorescent microscopic images showing intense HIF-1a (red) staining in a pimonidazole-related (green) CAIX (blue) area and almost absent HIF-
1a staining in another CAIX area in the same tissue section.
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Page 5 of 10CAIX areas far from pimonidazole positive hypoxic
areas (Figure 2i-j).
Relationship of markers with vasculature
Chronic hypoxia is an important feature of malignant
tumors, marked by a tissue oxygen gradient with lower
oxygen tensions farther from the blood vessels. The
expression of the endogenous markers in relation to the
vessels, with pimonidazole as a reference hypoxic mar-
ker, can provide valuable information about their useful-
ness as a marker of chronic hypoxia. To assess the
expression of the markers in relation to the vessels, frac-
tions were calculated at different distances from the
most nearby vessel in steps of 50 μm. In general,
hypoxic fraction and LDH-5 staining increased at larger
distances from the vessels. GLUT-1 and MCT4 were
present in variable fractions in the proximity of vessels,
but the expression increased about two to four-fold at >
150 μm from the vessels. All except four tumors exhib-
ited this “chronic hypoxic pattern”. These remaining
four showed no pimonidazole staining. Two examples of
the distribution of the markers in tumors with pimoni-
dazole (chronic hypoxic pattern) and without pimonida-
zole staining (non-hypoxic pattern) are shown in Figure
5. In one tumor (5a and b) with a large hypoxic fraction
(20%) pimonidazole binding increases steeply with dis-
tance from the vessels. GLUT-1, MCT4 and LDH-5 fol-
low this pattern but less steep, with a plateau reached
between 150-200 μm. MCT1 expression increases until
150-200 μm and decreases at larger distances. In the
second tumor (Figure 5c and 5d) all metabolic markers
were strongly expressed without any relationship with
the vessels and, in the absence of pimonidazole, not
depending on hypoxia. Low HIF-1a and CAIX expres-
sion was present in this tumor.
Figure 3 Correlations between the endogenous markers and pimonidazole. A schematic representation has been added; solid lines
represent a significant correlation, dashed lines a trend (p-value between 0.05-0.1). Percentages in the second table are mean values.
Figure 4 Colocalization of the various markers. (a-d) CAIX, LDH-5
and MCT4 show a significantly higher expression in pimonidazole
stained areas, MCT1 expression is not significantly different. (e and f)
Expression of MCT1 and MCT4 in CAIX negative and positive areas,
both are significantly higher in areas expressing CAIX. (g and h)
Increased expression of MCT1 and GLUT in MCT4 positive areas.
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compared to the other markers; in most tumors the
MCT1 fraction increased slightly till 100 μmf r o mt h e
vessels and remained constant or modestly decreased
again at larger distances. However, in the four tumors
without hypoxia, MCT1 expression was present close to
the vessels and decreased farther from the vessels.
Discussion
Hypoxia is an important feature of advanced head and
neck tumors, with a negative influence on prognosis
[12,20]. Evaluation of cellular responses to hypoxia can
be of clinical relevance in a prognostic and predictive
way and possibly for treatment adaptation. Until now no
endogenous marker has been found that strongly and
consistently correlates with hypoxia, so different kind of
analyses as presented here are crucial to elucidate the
role of the various proteins and the response of tumor
cells to a hypoxic microenvironment.
Although a global analysis of the overall expression of
a certain protein allows easy comparison between biop-
sies and between different studies, it is a huge simplifi-
cation of the true heterogeneous situation in a tumor
b i o p s y .T h e r e f o r e ,t og a i nm o r ei n s i g h ti nt h es p a t i a l
relationship between the metabolic markers and the
oxygenation status in the tumor, we additionally
assessed the expression of the proteins within and out-
side pimonidazole stained areas and the relation to the
vessels. With this analysis more markers show an evi-
dent relationship with pimonidazole than with a global
correlation analysis (Figure 4).
Of the endogenous hypoxia-related markers that we
examined, LDH-5 has the strongest relationship with
pimonidazole. LDH-5 is one of the target enzymes of HIF-
1 and has been described to have a strong association with
HIF-1a expression in tumor tissue sections [21,22]. The
high expression of LDH-5 in hypoxic areas is as expected;
it is one of the key enzymes in the glycolysis, the primary
Figure 5 Marker expression in different zones around the vessels. Zone analysis in a biopsy with a large hypoxic fraction (upper panels)
and a tumor with no pimonidazole staining (lower panels). Pimonidazole staining increases steadily at larger distances from the vessels (a). The
increase of GLUT, MCT4 and LDH-5 expression is less steep with a plateau reached between 150-200 μm (b). MCT1 expression increases until
150-200 μm, a slight decrease is noted at larger distances (a). In the tumour with no pimonidazole staining, a decrease in MCT1 expression (c)
and no increase of GLUT, MCT4 and LDH-5 expression (d) is observed at larger distances from the vessels.
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Page 7 of 10energy source in the absence of oxygen. The reason for a
considerable expression of LDH-5 outside hypoxic areas
could be the high rate of aerobe glycolysis (the Warburg
effect) as often observed in malignant tumors[4], although
alternative explanations are possible, as pyruvate can origi-
nate from other pathways as well[23]. It should be noted
that due to the similarity between LDH-5 and the other
LDH isoforms, there is a possibility of some cross-reactiv-
ity of the antibody.
CAIX is previously described to correlate weakly with
pimonidazole binding[13,24,25]. Despite the weak overall
correlation, CAIX fraction was significantly higher in the
hypoxic (pimonidazole positive) areas. This emphasizes
the strong association of this protein with hypoxia that
could not be found by a simple correlation analysis.
Interestingly, although all the endogenous markers, with
the exception of MCT1, are regulated by HIF-1[9,10], the
staining patterns and colocalization differ. An interesting
observation is the strong resemblance of the HIF-1a and
CAIX staining pattern (intermediate hypoxic areas). This
typical pattern circumferences the pimonidazole stained
area with a partial overlap (Figure 2i). The colocalization
of CAIX with HIF-1a is far from perfect, but more con-
cordant than that of GLUT-1, MCT4 and LDH-5 with
HIF-1a. The strong relationship of CAIX with HIF-1 is
known, with CAIX expression tightly controlled by HIF-
1[26]. In this context, an interesting observation is the
higher level of HIF-1a expression in hypoxia-related
CAIX areas than in CAIX areas separate from hypoxic
(pimonidazole stained) areas (Figure 2i/j). A possible
explanation of these findings could be the increased tran-
scription of HIF-1a without stabilization in the inter-
mediate hypoxic areas (areas with CAIX expression
without HIF-1a staining) and stabilization of HIF-1a in
severe hypoxic areas (areas overlapping and adjacent to
pimonidazole with CAIX and HIF-1a staining)[27]. It
could also indicate the transient presence of acute
hypoxic areas, which are reoxygenated before pimonida-
zole administration. It was shown in SiHa (human cervi-
cal squamous cell carcinoma) tumors that up to 20% of
the tumor cells were intermittently hypoxic over an 8-
hour period[28]. This explanation is less likely as CAIX
upregulation requires a longer period of hypoxia[29].
A third explanation could be the induction of HIF-1a
and consequent activation of CAIX through a hypoxia-
independent mechanism without stabilization of HIF-1a
under these conditions. An acidic tumor microenviron-
ment can influence HIF-1a and CAIX expression as well
[29,30]. In any case, there is little evidence for a HIF-1
independent CAIX activating mechanism[26].
Most markers showed a range of co-expression, but a
very strong spatial relationship was found between
GLUT-1 and MCT4 (Figure 4h). These showed a com-
parable, typical expression increasing at larger distances
from the vessels, with a two- to four-fold increase of the
fraction at 150-200 μm. This pattern and agreement
reflects their interrelated role in the glycolytic pathway
under hypoxic conditions, GLUT-1 for glucose import
and MCT4 for lactate export. LDH-5, one of the inter-
mediary enzymes in this pathway, shows a similar pat-
tern, but was not stained in the same section as MCT4
or GLUT-1, so the amount of colocalization could not
be calculated.
Although a small series, a positive correlation between
MCT4 and N-stage was found. Overexpression of
MCT4 in malignancies has been described in colorectal
cancer[31] and cervical carcinomas[32]. Except for a
trend towards shorter overall survival with MCT4 posi-
tive adenosquamous carcinomas of the cervix, no corre-
lations with clinicopathological data have been found
before. These findings indicate that MCT4 is a potential
marker for the aggressiveness of a tumor.
MCT1 expression in > 5% of the tumor area was pre-
sent in 14 of the 20 biopsies. MCT1 expression in
tumors has been described in lung cancer[33], brain
tumors[34] and cervical cancer[32]. However, in the
colonic epithelium, Lambert et al. found a decline in
expression associated with transition to malignancy[35].
In our study, MCT1 expression was present in oxic as
well as hypoxic areas, in contrast to the observation
made by Sonveaux et al. in biopsies of lung carcinomas
[ 6 ] .I ti si m p o r t a n tt on o t et h a ti no u rs t u d yad i f f e r e n t
antibody was used of which some aspecificity formally
can not be excluded, although other studies show good
r e s u l t sw i t ht h i sa n t i b o d ya sw e l l [ 7 , 3 6 ] .A st h ef r a c t i o n
MCT1 even increased at larger distance from the ves-
sels, it seems likely that MCT1, beside MCT4, plays a
role in lactate export in hypoxic areas. It is reasonable
to assume that in tumor cells, like in red blood cells,
depending on the substrate concentrations and pH,
MCT1 functions as either a lactate importer or assists
MCT4 in lactate export[37]. Either way, MCT1 has
already shown some potential as a therapeutic target in
vitro. Inhibition of MCT1 by lonidamine induced a
strong decrease in intracellular pH and loss of viability
of the tumor cells[34]. The MCT1 inhibitor a-cyano-4-
hydroxycinnamate blocks lactate-fueled respiration in
tumor cells and induces tumor growth retardation in a
mouse model[6]. Of interest is the strong correlation
and colocalization of MCT1 with CAIX (Figure 3 and
4e), affirming an important role in pH regulation as
described in melanoma and neuroblastoma[34,38].
In conclusion, metabolic markers show a strong but
irregular relation with hypoxia with obvious correlations
between markers, emphasizing the complex metabolic
regulatory system with a strong environmental (hypoxia,
pH) influence. Co-expression of markers provides addi-
tional information over single marker fractions. MCT4
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Page 8 of 10and GLUT-1 show a typical “diffusion-limited hypoxic”
pattern with a strong colocalization indicating activation
by similar stimuli. The positive correlation with N-stage
makes MCT4 a potential marker for tumor aggressive-
ness, but its exact value still has to be established.
MCT1 overexpression is present in the majority of the
advanced head and neck carcinomas in our series, in
non-hypoxic as well as hypoxic areas. The strong colo-
calization with CAIX suggests an important role in pH
regulation.
Conclusion
Endogenous metabolic and hypoxia-related markers can
be of great importance as prognostic and predictive
markers and are potential therapeutic targets. As the
various markers respond differently to hypoxia and
other environmental factors, a combination of these
markers could be used to predict treatment outcome
and select the appropriate patients for new targeted
therapies.
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